Abstract
Background: Studies have demonstrated that cysteine-rich 61 (CYR61) may be involved in tumor proliferation and invasion. However, the role of CYR61 plays in endocrine therapy response is largely unknown.
Patients and Methods: We tested the levels of CYR61 expression of 36 primary breast cancer patients who received neo-adjuvant endocrine therapy for at least 3 months by immunohistochemistry staining before and after administrating letrozole, an oral non-steroidal aromatase inhibitor (AI) for the treatment of hormone-responsive breast cancer. The expression levels of CYR61 and ki67 were compared between pre-treatment and post-treatment samples by using the paired t test. Chi-square test was used to determine the relationship between baseline CYR61 expression and clinical response. Results: In the clinical case series analysis, a positive correlation was observed between baseline CYR61 expression and clinical outcomes (p=0.02). CYR61 expression was significantly increased in the residual tumors after treatment (indicating insensitivity to endocrine therapy) compared with that in the baseline biopsy samples, which was irrespective of the efficacy of primary endocrine treatment. In addition, the ki67 level was significantly decreased after neo-adjuvant endocrine therapy, compared with that in the baseline samples. Conclusion: This study provides evidence that CYR61 may confer the sensitivity to letrozole treatment and may offer an opportunity to target CYR61 to improve endocrine resistance in ER-positive breast cancer.Keywords: Aromatase inhibitor, breast cancer, CYR61/CNN1, estrogen receptor, sensitivity.
Graphical Abstract
[1]
Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359(9324), 2131-2139.
[2]
Nicholson, R.I.; Gee, J.M. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer, 2000, 82(3), 501-513.
[3]
Menéndez, J.A.; Mehmi, I.; Griggs, D.W.; Lupu, R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr. Relat. Cancer, 2003, 10(2), 141-152.
[4]
Lau, L.F.; Lam, S.C. The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res., 1999, 248(1), 44-57.
[6]
Brigstock, D.R. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr. Rev., 1999, 20(2), 189-206.
[7]
Tsai, M.S.; Hornby, A.E.; Lakins, J.; Lupu, R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res., 2000, 60(20), 5603-5607.
[8]
Xie, D.; Nakachi, K.; Wang, H.; Elashoff, R.; Koeffler, H.P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res., 2001, 61(24), 8917-8923.
[9]
Saglam, O.; Dai, F.; Husain, S.; Zhan, Y.; Toruner, G.; Haines, G.K. III Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ. Hum. Pathol., 2014, 45(6), 1269-1275.
[10]
OKelly. J.; Chung, A.; Lemp, N.; Chumakova, K.; Yin, D.; Wang, H.J.; Said, J.; Gui, D.; Miller, C.W.; Karlan, B.Y.; Koeffler, H.P. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int. J. Oncol., 2008, 33(1), 59-67.
[11]
Tsai, M.S.; Bogart, D.F.; Castañeda, J.M.; Li, P.; Lupu, R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene, 2002, 21(53), 8178-8185.
[12]
Lin, J.; Huo, R.; Wang, L.; Zhou, Z.; Sun, Y.; Shen, B.; Wang, R.; Li, N. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol. Immunother., 2012, 61(5), 677-687.
[13]
Lai, D.; Ho, K.C.; Hao, Y.; Yang, X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res., 2011, 71(7), 2728-2738.
[14]
Cheng, J.; Lei, L.; Xu, J.; Sun, Y.; Zhang, Y.; Wang, X.; Pan, L.; Shao, Z.; Zhang, Y.; Liu, G. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J. Nucl. Med., 2013, 54(3), 333-340.
[15]
Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol., 1999, 17(5), 1474-1481.
[16]
Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; Hanna, W.; Jenkins, R.B.; Mangu, P.B.; Paik, S.; Perez, E.A.; Press, M.F.; Spears, P.A.; Vance, G.H.; Viale, G.; Hayes, D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol., 2013, 31(31), 3997-4013.
[17]
Yang, G.P.; Lau, L.F. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ., 1991, 2(7), 351-357.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
26
6